Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14458092 | 0.88 | PTGER4 (0.40) | PTGER4MAPTMEN1KMT2ANPSR1 | |
| SCHEMBL4410304 | 0.85 | PTGER4 (0.48) | PTGER4MAPTMEN1KMT2ANPSR1 | |
| SCHEMBL3289632 | 0.85 | PTGER4 (0.53) | PTGER4CA12CA9KDM4EALDH1A1 | |
| SCHEMBL2253345 | 0.81 | CA12 (0.55) | MAPTMEN1KMT2ANPSR1TSHR | |
| SCHEMBL3287289 | 0.79 | CA12 (0.49) | MAPTTSHRCA12CA1CA2 | |
| SCHEMBL10147610 | 0.77 | TSHR (0.48) | MAPTMEN1KMT2ANPSR1TSHR | |
| SCHEMBL9606730 | 0.76 | ALDH1A1 (0.49) | MAPTMEN1KMT2ANPSR1TSHR | |
| SCHEMBL3564213 | 0.76 | KDM4E (0.50) | MAPTMEN1KMT2ANPSR1TSHR | |
| SCHEMBL14458141 | 0.75 | CA12 (0.45) | MAPTMEN1KMT2ANPSR1TSHR | |
| SCHEMBL9654566 | 0.75 | PTGER4 (0.47) | PTGER4MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718689-B2 | Benzoisoindole derivatives and their use as EP4 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-7718689-B2 | Benzoisoindole derivatives and their use as EP4 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-7718689-B2 | Benzoisoindole derivatives and their use as EP4 receptor ligands | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| US-20090030061-A1 | {4-[4,9-bis(ethyloxy)-6-fluoro-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid; for treating chronic articular pain and bone disease such as osteoporosis, rheumatoid arthritis, periodontitis, or osteoarthritis | GLAXO GROUP LIMITED (GB) | 2009-01-29 | — | — | US | disclosed |
| US-20090030061-A1 | {4-[4,9-bis(ethyloxy)-6-fluoro-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid; for treating chronic articular pain and bone disease such as osteoporosis, rheumatoid arthritis, periodontitis, or osteoarthritis | GLAXO GROUP LIMITED (GB) | 2009-01-29 | — | — | US | disclosed |
| US-20090030061-A1 | {4-[4,9-bis(ethyloxy)-6-fluoro-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid; for treating chronic articular pain and bone disease such as osteoporosis, rheumatoid arthritis, periodontitis, or osteoarthritis | GLAXO GROUP LIMITED (GB) | 2009-01-29 | — | — | US | disclosed |
| EP-1986999-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093578-A1 | BENZOISOINDOLE DERIVATIVES AND THEIR USE AS EP4 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030061-A1 | {4-[4,9-bis(ethyloxy)-6-fluoro-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl]phenyl}acetic acid; for treating chronic articular pain and bone disease such as osteoporosis, rheumatoid arthritis, periodontitis, or osteoarthritis | OPRK1, OPRD1, FFAR1 | PTGER4 170/4885MAPT 4196/4885MEN1 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.